The intricacies of recent studies have not only enhanced our understanding of EphA2 involvement in the pathogenesis and various cellular processes of GBM but also provided an avenue for realising the potential of EphA2 as a therapeutic target for treating malignancies. The gene discussed is EPHA2; the disease is glioblastoma.